{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05696847",
            "orgStudyIdInfo": {
                "id": "17370"
            },
            "secondaryIdInfos": [
                {
                    "id": "I8F-MC-GPHV",
                    "type": "OTHER",
                    "domain": "Eli Lilly and Company"
                }
            ],
            "organization": {
                "fullName": "Eli Lilly and Company",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity",
            "officialTitle": "A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants (6 Years to 11 Years) With Obesity",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "a-study-of-tirzepatide-in-pediatric-participants-with-obesity"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-02-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-01-17",
            "studyFirstSubmitQcDate": "2023-01-17",
            "studyFirstPostDateStruct": {
                "date": "2023-01-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Eli Lilly and Company",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 13 weeks excluding the screening period."
        },
        "conditionsModule": {
            "conditions": [
                "Obesity"
            ],
            "keywords": [
                "Pediatrics",
                "Obesity",
                "Chronic weight management"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Tirzepatide",
                    "type": "EXPERIMENTAL",
                    "description": "Tirzepatide administered subcutaneously (SC)",
                    "interventionNames": [
                        "Drug: Tirzepatide"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo administered SC",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Tirzepatide",
                    "description": "Administered SC",
                    "armGroupLabels": [
                        "Tirzepatide"
                    ],
                    "otherNames": [
                        "LY3298176"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Administered SC",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration",
                    "description": "A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module",
                    "timeFrame": "Baseline through Week 13"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC0-tau) of Tirzepatide",
                    "description": "PK: AUC0-tau of tirzepatide",
                    "timeFrame": "Predose up to 168 hours postdose"
                },
                {
                    "measure": "PK: Maximum Concentration (Cmax) of Tirzepatide",
                    "description": "PK: Cmax of tirzepatide",
                    "timeFrame": "Predose up to 168 hours postdose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female participants with body mass index (BMI) \u2265 the 95th percentile for age and sex\n* Have failed to achieve adequate weight loss through lifestyle modification in the investigator's opinion\n* Female participants only: Determined as prepubertal Tanner Stage 1.\n\nExclusion Criteria:\n\n* Change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records\n* Have obesity induced by other endocrinologic disorders (for example, Cushing syndrome) or diagnosed monogenetic or syndromic forms of obesity\n* Have acute or chronic pancreatitis or a history of acute idiopathic pancreatitis; or have other GI disorders\n* Have a known clinically significant gastric emptying, have undergone weight loss surgery such as gastric bypass (bariatric) surgery or restrictive bariatric surger, or have endoscopic or device-based therapy for obesity or have had device removal within the last 6 months.\n* Have confirmed type 1 or type 2 diabetes mellitus\n* Have a history or current cerebrovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the IP; or may interfere with the interpretation of data",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "6 Years",
            "maximumAge": "11 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or",
                    "role": "CONTACT",
                    "phone": "1-317-615-4559",
                    "email": "ClinicalTrials.gov@Lilly.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",
                    "affiliation": "Eli Lilly and Company",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Atlanta Center of Medical Research",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30331 2012",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "404-881-5800"
                        },
                        {
                            "name": "Robert Riesenberg",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Lynn Health Science Institute",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73112",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "405-602-3939"
                        },
                        {
                            "name": "Carl Griffin",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "Baylor College of Medicine",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "713-798-0391"
                        },
                        {
                            "name": "Stephanie Sisley",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009765",
                    "term": "Obesity"
                }
            ],
            "ancestors": [
                {
                    "id": "D000050177",
                    "term": "Overweight"
                },
                {
                    "id": "D000044343",
                    "term": "Overnutrition"
                },
                {
                    "id": "D000009748",
                    "term": "Nutrition Disorders"
                },
                {
                    "id": "D000001835",
                    "term": "Body Weight"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5114",
                    "name": "Body Weight",
                    "relevance": "LOW"
                },
                {
                    "id": "M12701",
                    "name": "Obesity",
                    "asFound": "Obesity",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26186",
                    "name": "Overweight",
                    "relevance": "LOW"
                },
                {
                    "id": "M25307",
                    "name": "Overnutrition",
                    "relevance": "LOW"
                },
                {
                    "id": "M12684",
                    "name": "Nutrition Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000629749",
                    "term": "Tirzepatide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000054795",
                    "term": "Incretins"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M204206",
                    "name": "Tirzepatide",
                    "asFound": "DISKUS",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27905",
                    "name": "Incretins",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}